dementia

Insurers selling coverage in North Carolina, Pennsylvania and New York, among other states, say they won’t cover Leqembi with insurance offered on the individual market and through employers because they see the $26,000-a-year drug as experimental.

Clinics serving Alzheimer’s patients are working out the details of who will get treated with the new drug Leqembi. It won’t be for everyone with memory-loss symptoms.

The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors.

The "What's Health" panel examines the latest headlines about over-the-counter oral contraception, a new Alzheimer's drug, vaccines and more.

In addition to designing, testing and implementing the hearing intervention used in the multisite ACHIEVE study, USF researchers also trained the audiologists who used it and monitored the results.

It can be heartbreaking to let go of a hand-made rug or sweater that a loved one didn't quite finish. A group of volunteer knitters, quilters and other crafters offer some closure.

On Florida Roundup, we discuss how more Floridians are becoming caregivers for people with Alzheimer’s, and the number is only expected to increase. Also, what does it mean to be an autism-friendly city?

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

Minorities tend to be diagnosed at later stages of the disease, which would exclude them from use of Leqembi. Few Black people were included in the main trial of the drug.